Showing results (2251-2260 of 2,550) with videos related to

Sort By:
Pageof 255
The Journal of Biological Chemistry|September 5, 2003
Disruption of TR4 orphan nuclear receptor reduces the expression of liver apolipoprotein E/C-I/C-II gene clusterEungseok Kim, Shaozhen Xie, Shauh-Der Yeh, et al.
Neurogenetics|June 14, 2006
Investigation of autism and GABA receptor subunit genes in multiple ethnic groupsAnn L Collins, Deqiong Ma, Patrice L Whitehead, et al.
The International Journal of Clinical and Experimental Hypnosis|August 15, 2022
Suggestions in Hypnosis to Aid Pain Education (SHAPE) in People with Chronic Low-Back Pain: A Pilot Feasibility Randomized, Controlled TrialBrian W Pulling, Felicity A Braithwaite, G Lorimer Moseley, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2007
Design and optimization of imidazole derivatives as potent CXCR3 antagonistsXiaohui Du, Xiaoqi Chen, Jeffrey T Mihalic, et al.
The Pediatric Infectious Disease Journal|November 12, 2005
Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infantsClare L Collins, Jens U Ruggeberg, Gail Balfour, et al.
Molecular & Cellular Proteomics : MCP|February 11, 2012
The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathwaysMarcus L Hastie, Madeleine J Headlam, Nirav B Patel, et al.
Obesity (Silver Spring, Md.)|June 11, 2011
The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fatE Louise Thomas, James R Parkinson, Gary S Frost, et al.
The Journal of Clinical Investigation|September 7, 2021
Macrophage monocarboxylate transporter 1 promotes peripheral nerve regeneration after injury in miceMithilesh Kumar Jha, Joseph V Passero, Atul Rawat, et al.
Shock (Augusta, Ga.)|February 13, 2003
Characterization of the expression of inducible nitric oxide synthase in rat and human liver during hemorrhagic shockJoy L Collins, Yoram Vodovotz, Christian Hierholzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanomaA Gupta, S Love, A Schuh, et al.
Pageof 255